BioAge Labs (BIOA) Operating Leases (2025 - 2026)
BioAge Labs (BIOA) reported Operating Leases of $2.2 million for Q1 2026, down 12.79% on a YoY basis from $2.6 million in Q1 2025, and down 4.33% sequentially from $2.3 million in Q4 2025.
BioAge Labs (BIOA) Operating Leases (2025 - 2026) Analysis & Trends
BioAge Labs (BIOA) has 2 years of Operating Leases data on file, last reported at $2.2 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Leases fell 12.79% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 12.79% YoY), and the FY2025 full-year result was $2.3 million, changed N/A from the prior year.
- Operating Leases declined to $2.2 million in Q1 2026, from $2.3 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $2.6 million in Q1 2025 to a low of $2.2 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | BioAge Labs | 930.32 Mn | 930.32 Mn | -10.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.23 Mn |
| Dec 31, 2025 | 2.33 Mn |
| Sep 30, 2025 | 2.43 Mn |
| Jun 30, 2025 | 2.52 Mn |
| Mar 31, 2025 | 2.56 Mn |